skip to Main Content

A new publication explains the novel science behind the first molecular therapeutic for the rare neurogenetic disorder to advance into clinical development.

By Jennifer Gauntt, VMBS Communications – March 22, 2023

Read Article from VMBS
Related Article from Texas A&M Today
Related Article from Ultragenyx
Related Article from Spectrum News
Back To Top